ARN-75039 / Arisan Therap - LARVOL DELTA

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=94 | Completed | Sponsor: Arisan Therapeutics, Inc. | Recruiting ➔ Completed | N=64 ➔ 94 | Trial completion date: Jun 2025 ➔ Mar 2025

Enrollment change • Trial completion • Trial completion date • Infectious Disease

A Comparison of the Pharmacokinetic Properties of ARN-75039 Tablets With Excipients to Neat ARN-75039 in Hydroxypropyl Methylcellulose (HPMC) Capsules in Healthy Adult Participants Under Fed Conditions (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Arisan Therapeutics, Inc. | Recruiting ➔ Completed

Trial completion • Infectious Disease

A Comparison of the Pharmacokinetic Properties of ARN-75039 Tablets With Excipients to Neat ARN-75039 in Hydroxypropyl Methylcellulose (HPMC) Capsules in Healthy Adult Participants Under Fed Conditions (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Arisan Therapeutics, Inc.

New P1 trial • Infectious Disease

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: Arisan Therapeutics, Inc. | Suspended ➔ Recruiting

Enrollment open • Infectious Disease

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=64 | Suspended | Sponsor: Arisan Therapeutics, Inc. | Trial completion date: Oct 2023 ➔ Apr 2025 | Recruiting ➔ Suspended | Trial primary completion date: Jul 2023 ➔ Jan 2025

Trial completion date • Trial primary completion date • Trial suspension • Infectious Disease

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: Arisan Therapeutics, Inc.

New P1 trial • Infectious Disease